Sanofi reported a 14.4% increase in operating profit in the third quarter, reaching 4.6 billion euros, surpassing the forecast of 4 billion euros. Vaccine sales rose by 25.5%, reaching 3.8 billion euros, exceeding the analyst consensus of 3.2 billion euros.

The company stated that early shipments of flu vaccines and the Beyfortus drug, which protects newborns from respiratory viruses, were the main drivers of growth.

Sanofi is nearing the sale of a 50% stake in its Opella unit, valued at 16 billion euros, to fund the development of new drugs. Revenues from Dupixent increased by 23.8% to 3.48 billion euros, also exceeding analyst expectations.